The Effect of High Dose Rate Interstitial Implant on Early and Locally Advanced Oral Cavity Cancers: Update and Long-Term Follow-Up Study

Vedasoundaram, Parthasarathy; Ks, Abhishek Raghava; Periasamy, Kannan; Selvarajan, Gangothri; Sudhakar, K.; Kandasamy, Saravanan; Seenisamy, R.; Kumar, Aravind

doi:10.7759/cureus.7910

Cited by 3 publications

(10 citation statements)

References 15 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies 39 , 44 , 46 focused on the use of external beam RT (EBRT) with or without concurrent CT followed by brachytherapy (BT), two of them were clinical trials 44 , 46 and one was a retrospective cohort study. 39 The number of participants for each intervention group varied from 24 39 to 60 44 people.…”

Section: Resultsmentioning

confidence: 99%

“… 39 The number of participants for each intervention group varied from 24 39 to 60 44 people. One study 39 included patients with clinical stage III/IV oral cancer, one study 46 only included patients with stage III oral cancer, and another study 44 also included other clinical stages. The main outcomes assessed were OS, LRC, and CSS, which were evaluated in two 39 , 44 out of three 39 , 44 , 46 studies ( Table 5 ).…”

Section: Resultsmentioning

confidence: 99%

“…The main outcomes assessed were OS, LRC, and CSS, which were evaluated in two 39 , 44 out of three 39 , 44 , 46 studies ( Table 5 ).…”

Section: Resultsmentioning

confidence: 99%

“…Santos 39 assessed the use of EBRT up to 60 Gy plus concurrent CT followed by HDR-BT up to 24 Gy with a median follow-up of 44 months, reporting that the 4-year OS and LRC rate was 68% and 80%, respectively. Similarly, Vedasoundaram 46 assessed the use of EBRT 50 Gy plus CT with cisplatin followed by HDR-BT 21 Gy and reported a CR of 77.2%. Overall, this approach seems to be effective to treat patients with unresectable oral cancer, but more research about it is needed.…”

Section: Resultsmentioning

confidence: 99%

“…All selected studies were published in English language between 2011 and 2020. There were 15 retrospective cohort studies, 22,[24][25][26]28,34,[36][37][38][39][40][41][42]47,50 eight were prospective cohort studies, 19,23,29,32,33,35,44,46 six were RCTs, 18,21,27,30,31,43 four were clinical trials, 20,45,48,49 and none was case-control study. The sample size varied from 16 27 to 976 42 participants.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Anaya¹,

Amador²,

Acosta³

2021

CMAR

View full text Add to dashboard Cite

Purpose This review describes the current scientific evidence of therapeutic options in unresectable oral squamous cell carcinoma. Methods This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched MEDLINE (Via PubMed) to identify studies assessing treatments for unresectable oral squamous cell carcinoma. The methodological quality assessment of the included studies was performed using the Joanna Briggs Institute (JBI) checklist tool. The evidence was organized and presented using tables and narrative synthesis. Results Thirty-three studies met the eligibility criteria. Most studies had an observational design. The sample size varied from 16 to 916 participants. The methodology quality of the included studies ranged from 2.5 to 10 using the JBI tool. Overall, the optimal treatment of patients with unresectable oral cancer is challenging, so there is a sprinkling of studies assessing a variety of therapeutic options, such as radiotherapy, chemotherapy, concurrent chemoradiotherapy, immunotherapy, targeted therapy plus chemotherapy or radiotherapy, and gene therapy plus chemotherapy. Conclusion There is lacking evidence about the benefits of some therapeutic options for unresectable oral squamous cell carcinoma. Overall, these patients can be treated using a multimodal approach such as concurrent chemoradiotherapy or induction chemotherapy followed by chemoradiotherapy, which have shown good clinical outcomes. However, other options could be considered depending on the assessment of risk/benefits, tumor extension, and patient values and preferences.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…The main outcomes assessed were OS, LRC, and CSS, which were evaluated in two 39 , 44 out of three 39 , 44 , 46 studies ( Table 5 ).…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Anaya¹,

Amador²,

Acosta³

2021

CMAR

View full text Add to dashboard Cite

show abstract

Vascular events in patients with head and neck cancer: A systematic review and meta‐analysis

Monaghan,

Duckett,

Nguyen

et al. 2024

Head & Neck

View full text Add to dashboard Cite

ObjectiveTo assess the incidence of vascular events in patients with head and neck cancer.Review MethodsPrimary studies identified through April 2023. Meta‐analysis was performed.ResultsThere were 146 studies included in the systematic review. Rates of events were collected in the overall group, those with chemoprophylaxis, and those that underwent surgery, radiation, or chemotherapy. Of 1 184 160 patients, 4.3% had a vascular event. Radiation therapy had highest risk of overall events and stroke when compared to surgery and chemotherapy. Chemotherapy had a higher risk of stroke and overall events when compared to surgery.ConclusionsVascular events occur in 4%–5% of patients with head and neck cancer. Our data does not support the use of routine anticoagulation. Patients undergoing radiation therapy had the highest frequency of events.

show abstract

Is There Still a Place for Brachytherapy in the Modern Treatment of Early-Stage Oral Cancer?

Tuček

Vošmik

Petera

2022

Cancers

View full text Add to dashboard Cite

Brachytherapy (BT) involves the direct application of radioactive sources to the tumour. This technique is characterised by a steep dose gradient, the delivery of high-dose radiation to the target volume centre, and the sparing of surrounding healthy tissues. Low-dose-rate (LDR) BT and manual afterloading played an important role in the treatment of early-stage oral cancer, with treatment outcomes that were comparable to surgery. Interest in BT as a primary treatment for oral cancer has declined in recent years due to the emergence of better surgical techniques, the switch from LDR BT to high-dose-rate (HDR) BT (which has a higher risk of complications), and to advances in external beam radiotherapy (EBRT). At present, the main indications for BT are in the postoperative setting due to the superior dose conformity and better quality of life offered by BT versus EBRT. Postoperative BT can be administered as monotherapy in early-stage (T1N0) cancers and in combination with elective neck dissection or EBRT to treat larger or deeper tumours. BT yields excellent results for lip carcinoma in older patients and in tumours with unfavourable localisations. BT is an effective salvage therapy for local recurrences in previously-irradiated areas. Despite its many advantages, brachytherapy is a complex treatment requiring meticulous technique and close cooperation between the radiation oncologist, physicist, and surgeon.

show abstract

The Effect of High Dose Rate Interstitial Implant on Early and Locally Advanced Oral Cavity Cancers: Update and Long-Term Follow-Up Study

Cited by 3 publications

References 15 publications

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Vascular events in patients with head and neck cancer: A systematic review and meta‐analysis

Is There Still a Place for Brachytherapy in the Modern Treatment of Early-Stage Oral Cancer?

Contact Info

Product

Resources

About